ArticleOncology letters2016

Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.

Shuhui Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.